Evidence map›Paper›PMID 11104561›Full record

ArticleBritish journal of cancer2000

Screening breast cancer patients for Norwegian ATM mutations.

K Laake, P Vu, T I Andersen, B Erikstein, R Kåresen, P E Lonning, E Skovlund, A L Børresen-Dale

Abstract read
In one paragraph

Article in British journal of cancer, 2000. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

K LaakeDepartment of Genetics, The Norwegian Radium Hospital, Montebello, Oslo, 0310.
P Vu
T I Andersen
B Erikstein
R Kåresen
P E Lonning
E Skovlund
A L Børresen-Dale

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

483 Norwegian breast cancer patients were screened for six different ataxia telangiectasia mutated (ATM) mutations previously found to account for 83% of the disease alleles in Norwegian ataxia telangiectasia (AT) patients. Only one carrier was found. These results provide no evidence in favour of an excess risk of breast cancer associated with heterozygosity for classical AT mutations, but remain consistent with a maximum 2.4-fold increased risk.

Indexed as

AllelesAtaxia Telangiectasia Mutated ProteinsBreast NeoplasmsCell Cycle ProteinsDNA-Binding ProteinsDNA Mutational AnalysisDNA, NeoplasmFemaleGene FrequencyGenotypeHumansMass ScreeningNorwayProtein Serine-Threonine KinasesTumor Suppressor ProteinsAtaxia Telangiectasia Mutated ProteinsATM protein, humanCell Cycle ProteinsDNA-Binding ProteinsDNA, NeoplasmProtein Serine-Threonine KinasesTumor Suppressor Proteins

Identifiers

PMID11104561
PMCPMC2363448

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.